Basilea’s cancer pipeline slimdown continues; Aquestive looks to outlicense seizure drug in US
In February, Swiss biopharma Basilea announced an unusual move — it was looking to ditch its oncology assets in favor of its infectious disease pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
